BIIB Stock Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIIB from our risk checks.
Biogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$255.02 |
| 52 Week High | US$319.76 |
| 52 Week Low | US$194.63 |
| Beta | 0.13 |
| 1 Month Change | -3.56% |
| 3 Month Change | -9.87% |
| 1 Year Change | 30.28% |
| 3 Year Change | -9.58% |
| 5 Year Change | -27.67% |
| Change since IPO | 8,170.92% |
Recent News & Updates
Recent updates
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?
Jul 16
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet
Jun 28An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued
Apr 14Is Biogen (NASDAQ:BIIB) A Risky Investment?
Mar 27Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)
Jan 14Is Biogen (NASDAQ:BIIB) A Risky Investment?
Dec 25Biogen upgraded to buy at Stifel on lecanemab Alzheimer's treatment
Oct 13Biogen Inc. (NASDAQ:BIIB) Shares Could Be 44% Below Their Intrinsic Value Estimate
Oct 07Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug
Sep 29Biogen sells 271K square foot Cambridge, Mass. property for $592M
Sep 23Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Sep 19Biogen: Forecasting Suggests Buying At Historical Lows Advisable
Aug 29Lecanemab And Biogen's Path To Growth
Aug 22Shareholder Returns
| BIIB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | -1.5% | -2.7% |
| 1Y | 30.3% | 11.8% | 16.8% |
Return vs Industry: BIIB exceeded the US Biotechs industry which returned 11.8% over the past year.
Return vs Market: BIIB exceeded the US Market which returned 16.8% over the past year.
Price Volatility
| BIIB volatility | |
|---|---|
| BIIB Average Weekly Movement | 2.3% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: BIIB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: BIIB's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 8,725 | Chris Viehbacher | https://www.biogen.com |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
Biogen Inc. Fundamentals Summary
| BIIB fundamental statistics | |
|---|---|
| Market Cap | US$36.93b |
| Earnings (TTM) | US$2.66b |
| Revenue (TTM) | US$9.97b |
13.9x
P/E Ratio3.7x
P/S RatioIs BIIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIIB income statement (TTM) | |
|---|---|
| Revenue | US$9.97b |
| Cost of Revenue | US$2.37b |
| Gross Profit | US$7.60b |
| Other Expenses | US$4.94b |
| Earnings | US$2.66b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.40 |
| Gross Margin | 76.23% |
| Net Profit Margin | 26.72% |
| Debt/Equity Ratio | 43.5% |
How did BIIB perform over the long term?
See historical performance and comparison